Some 50 million Europeans live with multi-morbidity and their numbers are likely to grow. As they have complex health problems and need ongoing care, policymakers are alarmed by the challenge this poses to their health systems and social services.
The ICARE4EU project has looked at new approaches to integrated care and its findings are shared in five policy briefs:
- How to improve care for people with multi-morbidity?
- How to strengthen patient-centredness in caring for people with multi-morbidity
- How to strengthen financing mechanisms to promote care for people with multi-morbidity
- How can eHealth improve care for people with multi-morbidity
- How to support integration to promote care for people with multi-morbidity
To read more about the project and download the five policy briefs on caring for people with multi-morbidity from the euro.who.int website
Around 1.25 million people die every year on the world’s roads. Studies indicate that:
- almost half of all drivers exceed the speed limit
- drivers who are male, young and under the influence of alcohol are more likely to be involved in speed-related crashes
- road traffic accidents (RTAs) are the number one cause of death among young people aged 15–29 years
- RTAs are estimated to cost countries from 3–5% of GDP and push many families into poverty.
‘Managing speed’, a new report from WHO, suggests that excessive or inappropriate speed contributes to 1 in 3 road traffic fatalities worldwide. Measures to address speed prevent road traffic deaths and injuries, make populations healthier, and cities more sustainable.
To read more about speed management to save lives from the who.int website
Since 2001, EU rules have required the medicines we buy in the EU to contain a package leaflet which should provide us – the user, with clear information on the medicines we are taking – including the name of the product and the manufacturer, therapeutic indications, dosage, shelf life and adverse reactions.
The Commission has recently put forward recommendations on how they could be improved to better meet the needs of patients and healthcare professionals.
To read the recommendations on improved medicine packaging on the ec.europa.eu website
The latest report in the OECD’s series ‘Better policies for better health’ is “The Economics of Patient Safety: strengthening a value-based approach to reducing patient harm at national level”.
It makes the point that a principal objective of health care is to do no harm and to ensure that the benefits of treatment outweigh its deleterious effects. However, unnecessary harm to patients has been part of health care for as long as medicine has been practiced and continues to occur. In recent decades a greater research focus has examined and quantified the extent and costs of patient safety failure across countries and healthcare settings. The increasing complexity of health care also means a higher risk of harm requiring greater vigilance, focus and investment to ensure care is as safe and effective as possible.This report:
- estimates the cost of patient harm
- outlines a strategy for policy-makers and healthcare leaders to improve patient safety with limited resources.
To download the full report on the Economics of Patient Safety from the oecd.org website
France is recommending the Nutri-Score system – a straightforward labelling system that uses colour codes to guide consumers at a glance on the nutritional value of food products. This marks an important achievement for nutrition in the WHO European Region and it will build on other ongoing efforts in the country to create healthy food environments.
The United Kingdom already recommends traffic light labelling, a system that uses red, amber and green to indicate levels of fat, salt and sugar contained in food products. The Nutri-Score system that France intends to use employs a nutrient profiling system, based on the UK Food Standards Agency model, and classifies foods and beverages according to five categories of nutritional quality, indicated via a colour scale ranging from Green (grade A) to red (grade E).
For more information about the Nutri-score system of food labelling on the euro.who.int website
According to the latest factsheet from the WHO, 1 in 160 children world-wide has an autism spectrum disorder (ASD) and for most of them, the condition becomes apparent during the first 5 years of life.
ASD refers to a range of conditions characterised by some degree of impaired social behaviour, communication and language, and a narrow range of interests and activities that are both unique to the individual and carried out repetitively. ASDs begin in childhood and tend to persist into adolescence and adulthood.
For more information about autism spectrum disorders and to download the Parent Skills Training Package on the who.int website
The Innov8 technical handbook is a user-friendly resource as part of the Innov8 approach for reviewing national health programmes to leave no one behind. It gives detailed guidance and exercise sheets for each of the 8 steps of analysis that comprise the review process and includes background readings, country examples and analytical activities.
For more information and to download the handbook on the Innov8 approach for reviewing national health programes from the who.int website
The WHO have produced a protocol “Monitoring food and beverage marketing to children via television and the Internet” to help countries in the European Region gather data in a way that will support policy changes.
Most data on the prevalence of food and beverage marketing come from high-income, English-speaking countries,
specifically Australia, New Zealand, the UK and the USA. They show that the marketing of HFSS foods (high in saturated fats, salt and/or sugar) to children is highly prevalent, actively uses persuasive techniques likely to appeal to children and is present across multiple media, including broadcast television and social media online.
Continued monitoring is needed in these countries, to ensure that up-to-date evidence is available to inform and strengthen policy and that policies are adequately evaluated.
More data are urgently needed from other countries, however, to support the domestic policy-making process and to build a more representative global picture of food-marketing activity.
Studies conducted in accordance with this protocol will interest policy-makers, academic researchers, public health
practitioners and advocacy groups in the WHO European Region and worldwide.
The European Commission and its Scientific Committee on Health, Environmental and Emerging Risks (SCHEER) has published two Scientific Advices related to breast implants and health. They are on 1) new scientific information on the safety of PIP breast implants and 2) the possible association between breast implants and anaplastic large cell lymphoma (ALCL).
The first piece of advice concerns whether there is sufficient new scientific information on the safety of PIP breast implants to warrant an update of the 2014 SCENIHR Opinion and based on the scientific information it has gathered and evaluated, the SCHEER concludes that this is not the case at present.
The second piece of advice is on the state of scientific knowledge on a possible association between breast implants and anaplastic large cell lymphoma (ALCL). The SCHEER concluded that, at present, there is insufficient scientific information available to establish a methodologically robust risk assessment on the potential association of breast implants with the development of ALCL.
To download the full advice on the safety of PIP breast implants from the ec.europa.eu website
To download the full advice on the association between breast implants and ALCL from the ec.europa.eu website
A 5-year Patient Blood Management (PBM) programme in Western Australia resulted in a 28% reduction in hospital mortality, a 15% reduction in average hospital length of stay, a 21% reduction in hospital-acquired infections and a 31% decrease in heart attack or stroke. There was also a 41% reduction in the use of blood products, leading to a substantial cost saving as well.
PBM is a patient-focused, evidence-based and systemic approach to improve patient outcomes through the safe and rational use of blood and blood products and avoiding unnecessary transfusions. Essential elements of PBM include:
- preventing conditions that might result in the need for transfusion
- appropriate diagnosis
- good surgical and anaesthetic techniques
- the use of alternatives to blood transfusion and blood conservation.
The PBM approach has been endorsed and promoted by the WHO and is widely accepted as current best practice.
The EU has recently published two guides on Patient Blood Management (PBM), one for authorities and the other for hospitals.
To download the two guides on Patient Blood Management from the ec.europa.eu website